BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma

Go back to BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
(NASDAQ: BNTX) Delayed: 359.18 -13.47 (3.61%)
Previous Close $372.65    52 Week High
Open $370.74    52 Week Low
Day High $370.80    P/E N/A 
Day Low $344.81    EPS
Volume 5,638,714